Skip to main content
. 2020 Sep 10;23(2):313. doi: 10.1093/europace/euaa187

Table 3.

Effect on QTc and proarrhythmia of experimental pharmacological therapies for COVID-1936

QTc prolongation TdP risk
Chloroquine37–40 Moderate ↑ Low risk of TdP
Hydroxychloroquine41 Moderate ↑ Low risk of TdP
Azithromycin42–48 Moderate ↑ Very low risk of TdP
Lopinavir/ritonavir37 Moderate ↑ Low risk of TdP
Tocilizumab49 Mild ↑ or ↓ NR
Fingolimod Mild ↑ NR
Remdesivir NR NR
Interferon alfacon-1 NR NR
Ribavirin NR NR
Methylprednisolone NR NR

NR, not reported; TdP, torsade de pointes.